FDA Green Lights AstraZeneca, Merck's Lynparza for Metastatic Breast Cancer Post author:Sam Post published:January 11, 2018 Post category:BioPharma Lynparza is the first and only PARP inhibitor approved for use beyond ovarian cancer. Source: BioSpace You Might Also Like SoCal's USGI Medical Names Former ConMed Exec as CEO April 18, 2017 NOXXON Pharma AG Announces Prospectus Publication And Share Transfer To The Public Offering Compartment Of The Euronext Growth Market July 11, 2017 Aeterna Zentaris Forges $24M Tie-Up With Strongbridge January 16, 2018
NOXXON Pharma AG Announces Prospectus Publication And Share Transfer To The Public Offering Compartment Of The Euronext Growth Market July 11, 2017
